摘要
目的探讨血清CA15-3、CEA联合检测在乳腺癌诊治中的临床意义。方法采用酶联免疫吸附法检测。结果 CA15-3、CEA联合检测对于乳腺良性疾病与乳腺癌鉴别,差异无显著性(P>0.05);在对88例乳腺癌患者进行临床观察,出现骨、肺转移及复发时,CA15-3、CEA联合检测阳性率较高。结论乳腺癌患者CA15-3、CEA浓度较高时,提示肿瘤转移、复发并且预后不良。
Objective The aim of this study was to study the clinical value of carbohydrate antigen CA15-3 and CEA,in diagnosis and treatment of breast carcinoma.Methods The enzyme-inked immunosorbent assay（ELISA） Was ased to detect CA15-3 and CEA in breast cancer patients.Results No statistical diferences（P0.05）in serum levels of CA15-3 and CEA were found between benign tumor of breast and malignant tumor.The positive rates of CA15-3 and CEA in breast carcinoma with bone metastases,lung metastases and metastases.The serum levels of CA15-3 and CEA were markly correlated with metastases,recurrence and invasive area.Conclusion High levels of CA15-3 and CEA indicates that there were metastases and poor prognosis in breast cancer.
出处
《当代医学》
2011年第36期79-80,共2页
Contemporary Medicine
